:?

Rachel Woodford1,2, Paul Lorigan3,4, Deemesh Oudit5

  • 1Advanced Immunotherapy & Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

British journal of cancer
|February 18, 2026
PubMed
概括

瘤透淋巴细胞 (TIL) 疗法对晚期黑色素瘤患者显示有前途. 国家协调对于其复杂的实施,制造和成本效益高的整合到癌症治疗中至关重要.